Prognostic value of CYFRA 21 − 1 and Ki67 in advanced NSCLC patients with wild-type EGFR

被引：0
|
作者：
Tao Li
Qi Xie
Yang-Yang Fang
Yi Sun
Xiao Ming Wang
Zhu Luo
Gui-Ling Yan
Jian-Bo He
Xiao-Qun Zheng
机构：
[1] The Second Affiliated and Yuying Children’s Hospital of Wenzhou Medical University,Department of Laboratory Medicine
[2] Wenzhou Medical University,School of Laboratory Medicine and Life Sciences, The Key Laboratory of Laboratory Medicine
[3] Ministry of Education of China,Department of Respiratory Medicine
[4] The Second Affiliated and Yuying Children’s Hospital of Wenzhou Medical University,undefined
来源：
BMC Cancer | / 23卷
关键词：
CYFRA 21 − 1; Ki67; NSCLC; Wild-type EGFR; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Prognostic value of CYFRA 21-1 and Ki67 in advanced NSCLC patients with wild-type EGFR
    Li, Tao
    Xie, Qi
    Fang, Yang-Yang
    Sun, Yi
    Wang, Xiao Ming
    Luo, Zhu
    Yan, Gui-Ling
    He, Jian-Bo
    Zheng, Xiao-Qun
    BMC CANCER, 2023, 23 (01)
  • [2] To Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC with Wild-Type EGFR
    Jiang, D.
    Yu, Q.
    Zhang, X.
    Huang, F.
    Li, Y.
    Jin, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1053 - S1053
  • [3] Prognostic Value of Ki67 in Patients with Stage 1-2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor
    Jiang, Peng
    Jia, Mingzhu
    Hu, Jing
    Huang, Zhen
    Deng, Ying
    Lai, Li
    Ding, Shanshan
    Hu, Zhuoying
    ONCOTARGETS AND THERAPY, 2020, 13 : 10841 - 10850
  • [4] The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients
    Golmohammadi, Rahim
    Pejhan, Akbar
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2012, 62 (09) : 871 - 875
  • [5] Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib
    Winther-Larsen, Anne
    Fledelius, Joan
    Sorensen, Boe Sandahl
    Meldgaard, Peter
    LUNG CANCER, 2016, 94 : 81 - 87
  • [6] RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR
    Nakahara, Yoshiro
    Hosomi, Yukio
    Yomota, Makiko
    Okuma, Yusuke
    Takagi, Yusuke
    Iguchi, Mari
    Okamura, Tatsuru
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S490
  • [7] Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis
    Inno, Alessandro
    Di Noia, Vincenzo
    Martini, Maurizio
    D'Argento, Ettore
    Di Salvatore, Mariantonietta
    Arena, Vincenzo
    Schinzari, Giovanni
    Orlandi, Armando
    Larocca, Luigi Maria
    Cassano, Alessandra
    Barone, Carlo
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (02) : 513 - 520
  • [8] The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer
    Pathmanathan, Nirmala
    Balleine, Rosemary L.
    Jayasinghe, Upali W.
    Bilinski, Kellie L.
    Provan, Pamela J.
    Byth, Karen
    Bilous, A. Michael
    Salisbury, Elizabeth L.
    Boyages, John
    JOURNAL OF CLINICAL PATHOLOGY, 2014, 67 (03) : 222 - 228
  • [9] Prognostic Value of Ki67 Expression for Patients with Surgically Resected Hepatocellular Carcinoma: Perspectives from a High Incidence Area
    Bai, Kai
    Cao, Yi
    Huang, Qiaojia
    Jiang, Yi
    Lv, Lizhi
    CLINICAL LABORATORY, 2017, 63 (02) : 355 - 364
  • [10] Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
    Zheng, Hongmei
    Zhang, Yuting
    Zhan, Yuting
    Liu, Sile
    Lu, Junmi
    Feng, Juan
    Wu, Xia
    Wen, Qiuyuan
    Fan, Songqing
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6139 - 6150
12345